A Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia Gravis
Public ClinicalTrials.gov record NCT04650854. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label Extension Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia Gravis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to assess the safety, tolerability and efficacy of additional 6-week treatment cycles with rozanolixizumab in study participants with generalized myasthenia gravis (gMG).
Study identification
- NCT ID
- NCT04650854
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 165 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 3, 2021 (Actual)
- Primary completion
- Jan 25, 2024 (Actual)
- Completion
- Jan 25, 2024 (Actual)
- Last update posted
- Aug 20, 2026
2021 – 2024
United States locations
- U.S. sites
- 13
- U.S. states
- 10
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mg0007 50092 | Orange | California | 92868 | — |
| Mg0007 50099 | San Francisco | California | 94117 | — |
| Mg0007 50122 | Miami | Florida | 33136 | — |
| Mg0007 50120 | Miami | Florida | 33144 | — |
| Mg0007 50073 | Tampa | Florida | 33612 | — |
| Mg0007 50075 | Augusta | Georgia | 30912-0004 | — |
| Mg0007 50323 | Honolulu | Hawaii | 96817 | — |
| Mg0007 50114 | Indianapolis | Indiana | 46202 | — |
| Mg0007 50121 | Lexington | Kentucky | 40536-0284 | — |
| Mg0007 50077 | New York | New York | 10021 | — |
| Mg0007 50090 | Winston-Salem | North Carolina | 27157 | — |
| Mg0007 50096 | Philadelphia | Pennsylvania | 19104 | — |
| Mg0007 50113 | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 56 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04650854, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 20, 2026 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04650854 live on ClinicalTrials.gov.